Critical Insights for Treating Patients with Immune-Mediated Inflammatory Diseases

Immune-Mediated Inflammatory Diseases (IMIDs) afflict millions of people in the midst of working life, driving billions of dollars in healthcare costs, and new therapies are desperately needed

Our Vision: to drive changes to traditional drug discovery and treatment strategies by employing state-of-the-art methods and technologies to deeply understand patients and their underlying conditions

Our Mission: to partner with Pharma, Health companies, Payers, Big Data and Physicians to develop precision medicine diagnostics and new therapeutics that optimize treatment of IMID patients


IMIDomics Standardized Best Practices

IMID Patients

Standardized collection of clinical data by physicians is critical to reliable diagnosis of patients’ condition.

IMID Biobank

The cornerstone of a reliable biomedical research is the availability of high-quality biological samples.

Multiomics

High precision characterization of multiple molecular biomarkers, combined with reliable clinical data, is fundamental to accurately profile the patient condition.

Portal

IMIDomics portal is a proprietary tool that has been built specifically to integrate our data and allow in-depth inquiries


Our Story

  • 2006

    IMID Clinical Consortium

  • 2006

    Cross-sectional IMID Grant Awarded

  • 2007

    IMID-Biobank foundation

  • 2009

    ISO 9001 Certification

  • 2010

    First Cohort Collected

  • 2010

    Hudsonalpha Institute for Biotechnology Partnership

  • 2011

    Analysis and Database Build

  • 2012

    Longitudinal IMID cohort grant awarded

  • 2012 - ongoing

    Continued Cohort Collection and Analysis

  • 2015

  • 2015

    IMIDOMICS FOUNDED

  • 2016

    Celgene Collaboration

  • 2018

    BD Collaboration

  • 2019

    H2020 EU Framework Grant


Partnerships


Affiliations